Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
AARD•Outlook
- Company assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in Q3 2026
- Company remains in active discussions with FDA to resolve clinical hold for ARD-101 program
- Aardvark expects cash and investments to fund operations into late 2027
Overview
- US biopharma firm's Q2 net loss narrowed and beat analyst expectations
- Operating expenses fell yr/yr due to paused ARD-101 clinical trials and workforce reduction
- Company assessing unblinded Phase 3 data for ARD-101 and remains in talks with FDA
Result drivers and key details
- CLINICAL TRIAL PAUSE - Co attributed lower R&D expenses to voluntary pause of all ARD-101 clinical trials and subsequent FDA clinical hold
- WORKFORCE REDUCTION - Personnel-related costs increased prior to workforce reduction in June 2026, with severance expenses impacting G&A
- PHASE 3 DATA ASSESSMENT - Co is assessing unblinded HERO and OLE trial data to determine next steps for ARD-101 in PWS
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss |
Related News
Integra Resources laba bersih Q2 FY26 naik 12,78% jadi USD 12 juta; revenue naik 15,93% jadi USD 70,8 juta
ITRG•
Ferguson Enterprises Enters Bridge Term Loan Credit Agreement On August 11, 2026
FERG•
